References
1. Flanigan, K.M., Duchenne and Becker muscular dystrophies.Neurol Clin, 2014. 32 (3): p. 671-88, viii.
2. Gao, Q.Q. and E.M. McNally, The Dystrophin Complex: Structure,
Function, and Implications for Therapy. Compr Physiol, 2015.5 (3): p. 1223-39.
3. Fokkema, I.F., et al., LOVD v.2.0: the next generation in gene
variant databases. Hum Mutat, 2011. 32 (5): p. 557-63.
4. Aartsma-Rus, A., et al., Entries in the Leiden Duchenne
muscular dystrophy mutation database: an overview of mutation types and
paradoxical cases that confirm the reading-frame rule. Muscle Nerve,
2006. 34 (2): p. 135-44.
5. Muntoni, F., S. Torelli, and A. Ferlini, Dystrophin and
mutations: one gene, several proteins, multiple phenotypes. Lancet
Neurol, 2003. 2 (12): p. 731-40.
6. Aartsma-Rus, A., I.B. Ginjaar, and K. Bushby, The importance of
genetic diagnosis for Duchenne muscular dystrophy. J Med Genet, 2016.53 (3): p. 145-51.
7. Lee, J.A., C.M. Carvalho, and J.R. Lupski, A DNA replication
mechanism for generating nonrecurrent rearrangements associated with
genomic disorders. Cell, 2007. 131 (7): p. 1235-47.
8. Hastings, P.J., G. Ira, and J.R. Lupski, A
microhomology-mediated break-induced replication model for the origin of
human copy number variation. PLoS Genet, 2009. 5 (1): p.
e1000327.
9. Baskin, B., et al., Complex genomic rearrangements in the
dystrophin gene due to replication-based mechanisms. Molecular genetics
& genomic medicine, 2014. 2 (6): p. 539-547.
10. Mah, J.K., et al., A population-based study of dystrophin
mutations in Canada. Can J Neurol Sci, 2011. 38 (3): p. 465-74.
11. Moghadam-Kia, S., C.V. Oddis, and R. Aggarwal, Approach to
asymptomatic creatine kinase elevation. Cleveland Clinic journal of
medicine, 2016. 83 (1): p. 37-42.
12. Kuhn, R.M., D. Haussler, and W.J. Kent, The UCSC genome
browser and associated tools. Brief Bioinform, 2013. 14 (2): p.
144-61.